COMMUNIQUÉS West-GlobeNewswire

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
04/03/2024
MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) with interim data expected H1 2024 and topline data H2 2024 UK [...]
Sofwave Medical to Present Pure Impact™ Strength and Muscle Toning Module’s First U.S. Industry Reveal at the 2024 American Academy of Dermatology (AAD) Annual Meeting
04/03/2024
SAN CLEMENTE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, is excited to announce its [...]
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
04/03/2024
COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Biopharma Conference [...]
Safety Shot Appoints Serial Entrepreneur John Gulyas as Chairman of the Board
04/03/2024
With multiple 7-figure exits, John Gulyas will help lead Safety Shot in its ongoing efforts to become a leading wellness beverage brand. JUPITER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) ( [...]
Invitation to Participate in STOP-PC Clinical Trial
04/03/2024
AGOURA HILLS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) invites participation in our STOP-PC clinical trial which is now open for recruitment. Additional information can be [...]
Molecular Templates, Inc. Provides Interim Update
04/03/2024
Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase I study AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- [...]
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
04/03/2024
The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation of DMT VLS-01 is being developed as a rapid-acting [...]
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
04/03/2024
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody ® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 ZUG, Switzerland, March 4, 2024 – MoonLake Immunotherapeutics [...]
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
04/03/2024
VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and [...]
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
04/03/2024
CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction in non-fatal major [...]
Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology in Duchenne Muscular Dystrophy at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
04/03/2024
Bobcat mRNA TM technology is a novel linear mRNA platform able to encode large proteins Data showed restoration of muscular function in DMD mouse model BALTIMORE, March 04, 2024 (GLOBE NEWSWIRE) -- Elixirgen [...]
Tome Biosciences Forms Science and Technology Advisory Committee
04/03/2024
WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc. , the programmable genomic integration (PGI) company, announces the formation of its Science and Technology Advisory Committee (STAC) comprised [...]
4DMT to Participate in Upcoming Investor Conferences
04/03/2024
EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic [...]
Aruna BIO Establishes Stroke Advisory Board to Advance Lead Program, AB126 into the Clinic
04/03/2024
-The Stroke Advisory Board brings together distinguished experts in neurology and stroke to support the advancement of its neural exosome platform and lead program– -Phase 1b/2a clinical trial in acute ischemic stroke [...]
Vor Bio to Participate in Upcoming Investor Conferences
04/03/2024
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: [...]
Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024
04/03/2024
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of [...]
Osmol Therapeutics Appoints Ron Weitzman, M.D., as Interim Chief Medical Officer
04/03/2024
Company plans to initiate clinical program in mid-2024, followed by a Phase 2 study for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in patients with breast cancer NEW HAVEN, Conn., March 04, 2024 [...]
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
04/03/2024
MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. FDA NEWARK, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused [...]
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
04/03/2024
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of [...]

Pages